Trade Supernus Pharmaceuticals Inc - SUPN CFD

Trading Conditions

• Type: CFD
• Spread: 0.17
• Long position overnight funding adjustment: -0.02157%
• Short position overnight funding adjustment: -0.00065%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premium: 1%

Key Stats

• Prev. Close: 50.38
• Open: 51.27
• 1-Year Change: 63.38%
• Day's Range: 49.61 - 51.27

What is Supernus Pharmaceuticals Inc (SUPN)?

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company that develops and commercializes products primarily for the treatment of central nervous system disorders. The company’s portfolio includes therapies for conditions such as epilepsy, attention deficit hyperactivity disorder, and chronic pain. Supernus focuses on both proprietary and licensed products, emphasizing formulations designed to improve patient adherence and therapeutic outcomes. The company operates within the pharmaceutical industry, engaging in research, development, and marketing activities to address unmet medical needs in neurology and psychiatry.

Supernus Pharmaceuticals Inc Stock Price Today: Live Overview

The price today is shaped by ongoing trading as Supernus Pharmaceuticals Inc trades at $49.98. It has fluctuated from $49.53 to $51.37 during the day, showing a daily change of 0%.

FAQ: Supernus Pharmaceuticals Inc (SUPN)

What is the current price of SUPN stock?

The current price is $49.98.

Does SUPN pay dividends?

Supernus Pharmaceuticals Inc pays dividends via cash distributions (if applicable).

Does SUPN have a formal corporate presence or regional headquarters in the UAE?

Supernus Pharmaceuticals Inc has no official UAE office or subsidiary and operates via partners.

What is SUPN best known for?

Supernus Pharmaceuticals Inc is most famous for its development of central nervous system therapies.

What assets are typically shown together with SUPN?

Commonly shown alongside SUPN: Sanofi, Sumitomo Dainippon Pharma Co., Ltd., Corcept Therapeutics Inc